Key Takeaways
- All cancer patients aged 65+ should receive a comprehensive geriatric assessment (GA).
- When GA reveals vulnerabilities, GA‑guided management (GAM) must be integrated into the care plan.
- GAM reduces grade 3‑5 treatment toxicity by 20‑30% (GAP70+, GAIN trials).
- GAM applies to all systemic therapies, including chemotherapy, targeted agents, and immunotherapy.
- Multidisciplinary interventions (nutrition, PT/OT, pharmacy) improve quality of life and lower hospital admissions.
1. Bridging the Gap in Geriatric Cancer Care
In oncology, chronological age is often a poor proxy for physiological resilience. Cancer patients aged 65 and older represent the majority of our clinical volume, yet they remain a heterogeneous group where standard "performance status" assessments frequently fail. The core challenge in geriatric oncology is that traditional clinical judgment often misses subtle "age-associated vulnerabilities"—impairments in cognition, nutrition, or physical function that significantly predict treatment toxicity and survival.
The 2023 ASCO Guideline Update on the Practical Assessment and Management of Vulnerabilities in Older Patients represents the "coming of age" for this field. By synthesizing practice-changing data from recent Phase III trials, these guidelines provide a clear roadmap for moving beyond simple observation toward a multidisciplinary, evidence-based approach to care.
THE BOTTOM LINE Geriatric assessment (GA) is no longer an optional add-on; it is essential for high-quality care. All patients aged 65+ should receive a GA. Furthermore, for those with identified vulnerabilities, GA-guided management (GAM) must be integrated into the care plan to optimize outcomes and ensure goal-concordant care.
2. The Evidence: Why Geriatric Assessment (GA) is Practice-Changing
The 2023 update was driven by powerful "signals" from two landmark Phase III randomized clinical trials (RCTs): GAP70+ and GAIN. These trials provided definitive evidence that integrating GA findings into clinical decision-making significantly reduces the risk of severe treatment-related side effects.
Evidence-Based Benefits of GA-Guided Management (GAM)
| Trial | Patient Population | Serious Toxicity (Grade 3–5): GAM | Serious Toxicity (Grade 3–5): Standard Care | Statistical Significance |
|---|---|---|---|---|
| GAP70+ | Age 70+; Advanced/Incurable cancer (Solid tumors or lymphoma) | 51% | 71% | $P = .0001$ |
| GAIN | Age 65+; Solid tumors of any stage | 50.5% | 60.6% | $P = .02$ |
Notes: GAP70+ utilized a tailored GA summary and management recommendations sent to oncologists. GAIN utilized a multidisciplinary team (NP, Social Worker, PT/OT, Nutritionist, and Pharmacist) to implement interventions.
Beyond toxicity, other trials have demonstrated the breadth of GA’s impact:
- GERICO Trial: Showed that GA-guided interventions led to significantly higher chemotherapy completion rates (45% vs. 28%) in patients with colorectal cancer.
- INTEGERATE Trial: Found that integrated oncogeriatric care improved health-related quality of life (QOL) and reduced unplanned hospital admissions.
3. The New Standard: Recommendation 1.1
The Expert Panel has issued a strong, high-quality evidence recommendation that establishes a new standard of care.
Recommendation 1.1: All patients with cancer aged 65 and over with geriatric assessment (GA)-identified impairments should have GA-guided management (GAM) included in their care plan.
It is critical to distinguish between assessment and management: while every patient 65+ should be assessed, the mandate for GAM applies specifically when those assessments reveal vulnerabilities.
Amendment 1.1a significantly expands the scope of this recommendation. While the 2018 guidelines focused primarily on chemotherapy, the 2023 update clarifies that GAM is required for older adults receiving any systemic therapy, including targeted therapy and immunotherapy.
What defines GAM? Geriatric Assessment-guided Management is a proactive, two-pronged strategy:
- Treatment Modification: Using GA results to inform the initial cancer treatment decision (e.g., choosing single-agent vs. doublet therapy or implementing a 20% dose reduction with escalation as tolerated).
- Targeted Interventions: Addressing specific impairments through goal-concordant care, such as referrals to a multidisciplinary team or specific supportive care measures.
4. The Practical Solution: Introducing the PGA
A major barrier to implementing GA has been the perceived time and resource burden. In response, the ASCO Older Adults Task Force partnered with the Cancer and Aging Research Group (CARG) to develop the Practical Geriatric Assessment (PGA) through a formal Delphi consensus process.
The PGA is designed for real-world efficiency. Many of its components are patient-reported, allowing them to be completed outside of the time spent with a provider. While the PGA as a composite tool is not yet psychometrically validated, every individual component is a validated measure with specific scoring thresholds:
- Physical Function: Screening for $\geq 1$ fall in the last 6 months or a 4-meter gait speed $\geq 4$ seconds (indicating high risk).
- Cognitive Function: Using the Mini-Cog; a score of 0–2 indicates a high likelihood of impairment and requires explicit written instructions and caregiver involvement.
- Functional Status: Any limitation in Instrumental Activities of Daily Living (IADLs) such as managing medications, transportation, or finances.
- Nutrition: Identifying weight loss $> 6.6$ lbs ($3$ kg) over the past three months.
- Social Support: Assessing the availability of a health care proxy and instrumental support at home.
- Emotional Health: Screening for anxiety (PROMIS) or depression (GDS-5).
- Comorbid Conditions: Evaluating how other health issues (like heart or kidney disease) interfere with daily life or treatment tolerability.
5. Clinical Outcomes: Beyond Toxicity Reduction
Implementing GA and GAM does more than just lower toxicity; it optimizes the entire trajectory of cancer care:
- Avoidance of Over/Undertreatment: GA provides the nuance needed to identify "fit" patients who can tolerate full-intensity treatment and "frail" patients who require a gentler approach to maintain independence.
- Improved Communication: Trials like COACH demonstrated that GA summaries lead to more oncologist-initiated conversations about aging-related concerns, resulting in higher patient and caregiver satisfaction.
- Advance Care Planning: The GAIN trial showed a significant increase in advance directive completion (28.4% vs 13.3%), ensuring care remains aligned with patient values.
- Goal-Concordant Care: By involving a multidisciplinary team, clinicians can address non-oncologic issues (like polypharmacy and falls) that are often more meaningful to the patient’s daily life than the cancer itself.
6. Addressing the Barriers to Implementation
Surveys of oncology providers consistently highlight four barriers to GA uptake: Time, Resources, Training, and Knowledge.
The Expert Panel addressed these hurdles directly in the 2023 update:
- Time/Resources: The PGA's reliance on patient-reported outcomes and streamlined tools minimizes clinic footprint.
- Training: ASCO has produced specific YouTube training videos and online resources to help staff learn to conduct and score assessments quickly.
- Flexibility: The guidelines emphasize that while the domains are essential, the method of delivery is flexible. Practices can adapt the GA to their specific setting, whether using a geriatrician consultation model or a nurse-practitioner-led multidisciplinary team.
7. Conclusion & Patient Advocacy Takeaways
The evidence is clear: we can no longer treat older adults using a one-size-fits-all model. Geriatric assessment is the most powerful tool we have to personalizing oncology, reducing harm, and honoring the goals of our patients.
Actionable Takeaways for Patients and Caregivers:
- Specifically Request a "Geriatric Assessment": If you or a loved one is 65 or older, ask your oncology team for a formal assessment of aging-related risks before treatment begins.
- Discuss "Function" as a Vital Sign: Ensure your doctor knows about recent falls, memory changes, or difficulties with daily chores, as these should directly influence your treatment plan.
- Advocate for the Multidisciplinary Team: Ask if your care can involve a pharmacist to review medications or a physical therapist to help maintain strength during treatment.
Geriatric oncology has moved from a niche subspecialty to a foundational element of modern cancer care. By embracing these guidelines, we ensure that as our patients age, their care remains as robust and personalized as the science allows.